COVID-19 and Genitourinary Cancers
Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
January 27, 2022
Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months
January 7, 2022
Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer.
December 27, 2021
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up.
December 23, 2021
COVID-19 Infection, More Likely than Vaccines to Cause Rare Cardiovascular Complications
December 14, 2021
Delivering exercise medicine to cancer survivors: has COVID-19 shifted the landscape for how and who can be reached with supervised group exercise?
November 9, 2021
Continued Androgen Signalling Inhibition improves Cabazitaxel Efficacy in Prostate Cancer.
November 9, 2021
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
October 18, 2021
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.
October 13, 2021
Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
October 8, 2021
COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center.
September 27, 2021
Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
September 15, 2021
Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic.
August 11, 2021